Skip to content

A Prospective Trial Comparing Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) and Conventional Open Thyroidectomy

A Prospective Trial Comparing Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) and Conventional Open Thyroidectomy

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06225765
Enrollment
40
Registered
2024-01-26
Start date
2024-07-01
Completion date
2026-09-30
Last updated
2024-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Thyroid Nodule, Suspicious Malignant Thyroid Nodule

Keywords

Thyroid nodule

Brief summary

To determine if transoral endoscopic thyroidectomy vestibular approach (TOETVA) is a safe and effective procedure compared to traditional open thyroidectomy. Surgical outcomes, patients' satisfaction, voice and swallowing outcomes will be assessed.

Detailed description

This is a prospective case control study involving a total 40 patients, with 20 stratified into the test group receiving surgery under transoral endoscopic thyroidectomy vestibular approach (TOETVA) and 20 patients to the control group under traditional open approach. Subjects will be assigned to either group without randomization. Patients satisfactory score, voice and swallowing quality of life outcomes will be assessed using Voice Handicap Index (VHI) and MD Anderson Dysphagia Inventory (MDADI) outcomes. Surgical outcomes, for instance, lower lip numbness, skin injury, operative time, blood loss, vocal cord paralysis, temporary and permanent hypoparathyroidism will be assessed.

Interventions

PROCEDURETransoral endoscopic thyroidectomy vestibular approach (TOETVA)

Remote access thyroid surgery

PROCEDURETraditional Open Thyroidectomy

Open thyroidectomy via trans-cervical approach

Sponsors

Tseung Kwan O Hospital, Hong Kong
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Prospective case control study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Benign thyroid nodule less than 4cm * Suspicious malignant thyroid nodule less than 2cm, suitable for transoral endoscopic surgery

Exclusion criteria

* Patients under 18 years old * Contraindication to general anaesthesia * Vulnerable population (e.g. Cognitive impairment, pregnant) * Previous anterior neck surgery * Previous radiotherapy at the head and neck region * Malignant thyroid nodule \> 2cm * Presence of another malignancy, lateral neck, or distant metastasis * Retrosternal goitre * Cervical spine disease precluding extension of the neck * Obesity with BMI \> 35kg/m2 * Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic intervention * Untreated active infection * Non-correctable coagulopathy * Emergency surgery

Design outcomes

Primary

MeasureTime frameDescription
Complication rate and typesPost-operative 2 weeksLower lip numbness, skin bruising or injury, wound infection, vocal cord paralysis, temporary hypoparathyroidism
Patient's satisfactory scorePost-operative day 1Visual analogue scale 0-10
Post-operative painPost-operative day 1Visual analogue scale 0-10
Voice quality of lifePost-operative day 1Voice Handicap Index - 30 assessing functional, physical and emotional scales
Swallowing quality of lifePost-operative day 1MD Anderson dysphagia inventory (MDADI)

Secondary

MeasureTime frameDescription
Operative timeIntra-operativelyMinutes
Blood lossIntra-operativelyVolume
Rate of conversion to open surgeryIntra-operativelyPercentage of conversion
Inpatient stayAn average of 0-2 days after the operationNumber of days of inpatient stay

Countries

Hong Kong

Contacts

Primary ContactCherrie Ng
cherrieng@ent.cuhk.edu.hk+85235051409
Backup ContactThomas Hui
hsc526@ha.org.hk+85239493549

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026